Complement Therapeutics : First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study —…
Continue Reading-
First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat
First patient dosed in Gesynta Pharma’s endometriosis trial of vipoglanstat — Hadean Ventures Home Portfolio…
Continue Reading -
Neuro Event Labs Receives FDA 510(k) Clearance for the Nelli® Seizure Monitoring System
Neuro Event Labs Receives FDA 510(k) Clearance for the Nelli® Seizure Monitoring System — Hadean…
Continue Reading -
Step Pharma announces completion of €38 million Series C financing
Step Pharma announces completion of €38 million Series C financing — Hadean Ventures Home Portfolio…
Continue Reading -
Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
Complement Therapeutics Receives FDA IND Clearance...
Continue Reading -
Ribbon Bio and Scala Biodesign into Powerful Partnership Focused on Customers
Ribbon Bio and Scala Biodesign into Powerful Partnership Focused on Customers — Hadean Ventures Home…
Continue Reading -
ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
ARTHEx Biotech Upsizes Series B Financing Round to $87M...
Continue Reading -
Hadean Ventures is looking for an Investment Intern
Investment Intern
Continue Reading -
Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and Hadean Growth Fund Join Strong Investor Syndicate
Gesynta Pharma Announces Second Closing of Series B Now Totaling SEK 347m – HealthCap and…
Continue Reading -
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes…
Continue Reading